Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Belite Bio, IncNASDAQ: BLTE

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 40.42M shares rose 21.6% year over year, ahead of the +19.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.6% holds above the trailing-twelve-month pace of +19.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
40.42M+0.6% QoQ
Last fiscal yearDec 2025
33.54M+9.8% YoY
LTMSep 2026
38.5M+19.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.6%——
1 year+9.8%——
3-year CAGR+18.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
33.54M USD
Year-over-year change
+9.8%
4-year CAGR
+8.6%

Weighted Avg Shares vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's LTM Sep 2026 weighted avg shares of 38.5M shares is the 5th highest of the 6 companies compared; the peer median is 77.28M shares.
  • Its year-over-year change of +19.1% is the 4th highest of 6, against a peer median of +27.7%.
  • Over three fiscal years its annual growth of +18.9% compares with a peer median of +25.2%.
BLTE Competitors Peer median
Weighted Avg Shares for BLTE and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
BLTEBelite Bio, IncLTM Sep 202638.5M +19.1%+18.9%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
Peer median (excluding BLTE) 77.28M+27.7%+25.2%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development7.42M8.87M24.84M29.94M45.38M
Selling, General & Admin2.38M3.95M6.82M10.06M38.83M
Operating Expenses9.8M12.82M31.67M40M84.21M
Depreciation & Amortization30K198K399K449K464K
EBITDA(9.64M)(12.43M)(31.2M)(35.67M)(77.15M)
EBITDA Margin—————
Operating Income(9.8M)(12.82M)(31.67M)(40M)(84.21M)
Operating Margin—————
Interest Income5K23K74K3.74M0
Interest Expense016K25K20K0
Other Income / Expenses131K173K45K3.86M6.6M
Income Before Tax(9.67M)(12.65M)(31.62M)(36.14M)(77.61M)
Pre-Tax Margin—————
Income Tax Expense009K6K0
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Net Margin—————
EPS (Basic)(0.40)(0.63)(1.19)(1.18)(2.31)
EPS (Diluted)(0.40)(0.63)(1.19)(1.18)(2.31)
Weighted Avg Shares24.1M19.98M26.59M30.54M33.54M
Weighted Avg Shares (Diluted)24.1M19.98M26.59M30.54M33.54M

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.